Herpes zoster (HZ) is common in older people, with a lifetime risk 25%. The main risk factors are advanced age and immunosupration. People with a rheumatic and musculoskeletal disease have an overall high risk for ringworm. Eular – European alliance of associations for rheumatology – recommends that HZ vaccination is considered with an autoimmune and inflammatory RMD in high -risk patients. Live vaccines in patients on immunospressive therapy are difficult; New non-live vaccines may change live-attained versions, but when the final recommendations were developed, the safety and efficacy of the subunit zoster vaccine was not yet investigated in RMD patients.

The new work submitted to the 2025 Annual Euller Congress in Barcelona focuses on the recruitment Zoster Vaccine (RZV), which includes the recreational Glycoprotein E -CD4+ T -key goals of T -cells. The essence describes the tolerance and safety of RzV in patients with inflammatory rheumatic and musculoscalelles (IRMD), showing interim data from an ongoing study.

Overall, 150 adults with rheumatoid arthritis (RA), axial spondyloarthritis (XSPA), or giant cell arteritis (GCA), who had an indication to receive RZV, were potentially involved. Of these, there was a history of HZ of 21.3%, and all received RZV at month 0; 90% also received a dose at month 2. Security assessment was done in 2 months, 3, 6 and 12 months.

Most of the adverse incidents (AE) took place within a few days after vaccination. Overall, 139 (46.8%) localized and 158 (53.2%) normalized up to AE Month 3. At that time, the pain at the place of injection was most often AE, 32.7%reported by patients. This is followed by fever (14.1%), fatigue (9.4%), musculoskeletal pain (8.1%), swelling (6.4%) on the injection site and redness on the injection site (6.4%). Infections (4.7%), deteriorating disease (3.7%) and other AES (7.7%) were reported to be 3.

Patients were informed by patients in the months of 2, 3, 6 and 12, but only 1.6–8.6% of these met the predetermined inflammatory criteria. 3 patients required to be hospitalized due to provoking the disease – with 2 GCA and with 1 RA. Lead writer Utah Kiltz said “In the 12 -month -old period, it can be interpreted as a low rate of events.”

Overall, 10 serious AEs were reported in 9 patients during follow-ups (3 flares, 4 knees and 3 comrades), but no patient informed AE about special interest or success infection. Note, deformities were not considered related to vaccination.

The authors concluded that most of the patients tolerated RZV well, with only a few flair and serious AE reports. These findings are assured to rheumatologists and future vaccine recipients, and support RZV security for patients with IRMD.